This collection of articles offers a comprehensive overview of recent advances in cancer biomarkers and their importance in precision oncology, spanning a diverse array of tumor types and clinical challenges. The assembled studies highlight breakthroughs in early detection, prognostic and predictive markers, and novel therapeutic targets, with a strong emphasis on integrating molecular and bioinformatics approaches. Topics include the clinical potential of autoantibodies in non-small cell lung cancer, the regulatory mechanisms and prognostic significance of proteins such as HJURP and DAP3 in gastric and liver cancers, the use of circulating tumor cells for non-invasive genetic testing in colorectal cancer, and the emerging role of TEM8 as a solid tumor biomarker. Additionally, the abstracts explore the value of multidimensional risk modeling, immune pathway analyses (including STING signaling), the prognostic utility of the glucose-to-lymphocyte ratio, and the diagnostic significance of advanced imaging biomarkers like ADC values in rectal cancer. The collection also addresses particular clinical scenarios, such as the unique diagnostic challenges in Ewing sarcoma and the overlap of molecular pathways between lung cancer and myocardial infarction, while underlining the critical need for personalized therapy guided by precise molecular features. Together, these studies underscore the momentum and breadth of cancer biomarker research, with direct implications for improving early diagnosis, treatment stratification, and patient outcomes.
The global burden of cancer is on the rise, prompting an urgent need for innovative diagnostic and therapeutic strategies. Recent advancements in molecular technologies have revolutionized our understanding of cancer biology, allowing researchers to delve into the intricate mechanisms of carcinogenesis at the molecular level. Multi-omics approaches, encompassing genomics, epigenomics, transcriptomics, and proteomics, have provided comprehensive insights into the complexities of cancer as a systemic disease.
These advanced technologies have empowered researchers to identify specific molecular signatures associated with various carcinogenic compounds. Furthermore, the development of highly sensitive detection methods for cancer-specific molecular alterations has significantly advanced liquid biopsy techniques and facilitated early cancer detection.
The primary objective of this Research Topic is to serve as a platform for sharing the latest research findings on diverse molecular biomarkers and their applications in cancer detection, diagnosis, and prognosis. Recent breakthroughs in liquid biopsy, single-cell sequencing, and functional genetic association studies using omics technologies have transformed the landscape of cancer management protocols.
This issue aims to highlight specialized areas of cancer research, providing up-to-date insights into the field.
Topics of Interest include, but are not limited to:
• Genomic and Epigenomic Biomarkers of Cancer
• Proteomic and Metabolomic Biomarkers of Cancer
• Single Cell Analysis
• Liquid Biopsy in Cancer Diagnosis
• Transcriptomics in Cancer Research
• Genetic Association Studies in Cancer
• MicroRNA and Non-coding RNA Biomarkers in Cancer
• Immune Biomarkers and Immunotherapy Response Prediction
• Circulating Tumor Cells and Circulating Tumor DNA in Cancer Monitoring
• Metabolic Biomarkers and Metabolic Reprogramming in Cancer
• Tumor Microenvironment Biomarkers and Therapeutic Targeting Strategies
• Cancer and Gender Medicine
This collection of articles offers a comprehensive overview of recent advances in cancer biomarkers and their importance in precision oncology, spanning a diverse array of tumor types and clinical challenges. The assembled studies highlight breakthroughs in early detection, prognostic and predictive markers, and novel therapeutic targets, with a strong emphasis on integrating molecular and bioinformatics approaches. Topics include the clinical potential of autoantibodies in non-small cell lung cancer, the regulatory mechanisms and prognostic significance of proteins such as HJURP and DAP3 in gastric and liver cancers, the use of circulating tumor cells for non-invasive genetic testing in colorectal cancer, and the emerging role of TEM8 as a solid tumor biomarker. Additionally, the abstracts explore the value of multidimensional risk modeling, immune pathway analyses (including STING signaling), the prognostic utility of the glucose-to-lymphocyte ratio, and the diagnostic significance of advanced imaging biomarkers like ADC values in rectal cancer. The collection also addresses particular clinical scenarios, such as the unique diagnostic challenges in Ewing sarcoma and the overlap of molecular pathways between lung cancer and myocardial infarction, while underlining the critical need for personalized therapy guided by precise molecular features. Together, these studies underscore the momentum and breadth of cancer biomarker research, with direct implications for improving early diagnosis, treatment stratification, and patient outcomes.
The global burden of cancer is on the rise, prompting an urgent need for innovative diagnostic and therapeutic strategies. Recent advancements in molecular technologies have revolutionized our understanding of cancer biology, allowing researchers to delve into the intricate mechanisms of carcinogenesis at the molecular level. Multi-omics approaches, encompassing genomics, epigenomics, transcriptomics, and proteomics, have provided comprehensive insights into the complexities of cancer as a systemic disease.
These advanced technologies have empowered researchers to identify specific molecular signatures associated with various carcinogenic compounds. Furthermore, the development of highly sensitive detection methods for cancer-specific molecular alterations has significantly advanced liquid biopsy techniques and facilitated early cancer detection.
The primary objective of this Research Topic is to serve as a platform for sharing the latest research findings on diverse molecular biomarkers and their applications in cancer detection, diagnosis, and prognosis. Recent breakthroughs in liquid biopsy, single-cell sequencing, and functional genetic association studies using omics technologies have transformed the landscape of cancer management protocols.
This issue aims to highlight specialized areas of cancer research, providing up-to-date insights into the field.
Topics of Interest include, but are not limited to:
• Genomic and Epigenomic Biomarkers of Cancer
• Proteomic and Metabolomic Biomarkers of Cancer
• Single Cell Analysis
• Liquid Biopsy in Cancer Diagnosis
• Transcriptomics in Cancer Research
• Genetic Association Studies in Cancer
• MicroRNA and Non-coding RNA Biomarkers in Cancer
• Immune Biomarkers and Immunotherapy Response Prediction
• Circulating Tumor Cells and Circulating Tumor DNA in Cancer Monitoring
• Metabolic Biomarkers and Metabolic Reprogramming in Cancer
• Tumor Microenvironment Biomarkers and Therapeutic Targeting Strategies
• Cancer and Gender Medicine